Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.
Walewski J, Kraszewska E, Mioduszewska O, Romejko-Jarosińska J, Hellmann A, Czyz J, Hołowiecki J, Kopera M, Grosicki S, Komarnicki M, Rumianowski L, Kuliczkowski K, Wróbel T, Dwilewicz-Trojaczek J, Robak T, Warzocha K, Załuski J, Wójcik E, Dmoszyńska A, Walter-Croneck A; Polish Lymphoma Research Group. Walewski J, et al. Among authors: kraszewska e. Med Oncol. 2001;18(2):141-8. doi: 10.1385/mo:18:2:141. Med Oncol. 2001. PMID: 11778760 Clinical Trial.
CHOP-21 for unfavorable Hodgkin's lymphoma. An exploratory study.
Walewski J, Lampka E, Tajer J, Osiadacz W, Kraszewska E, Krzyzanowska JB, Meder J. Walewski J, et al. Among authors: kraszewska e. Med Oncol. 2010 Jun;27(2):262-7. doi: 10.1007/s12032-009-9202-3. Epub 2009 Mar 25. Med Oncol. 2010. PMID: 19319702
A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time.
Hliniak A, Gwiazdowska B, Szutkowski Z, Kraszewska E, Kukolowicz P, Jarzabski A, Sochacka B, Mazurkiewicz M, Paprota K, Oliskiewicz W, Zadrozna O, Milecki P, Kubiak M, Czopkiewicz L, Jagas M, Góźdź S, Wieczorek A, Woytowicz A, Cisowska B, Magdziarz H, Nowakowski S, Kośniewski W, Laskosz I, Serafin A, Gradoń E. Hliniak A, et al. Among authors: kraszewska e. Radiother Oncol. 2002 Jan;62(1):1-10. doi: 10.1016/s0167-8140(01)00494-7. Radiother Oncol. 2002. PMID: 11830307 Clinical Trial.
Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (Revised II).
Rupinski M, Zagorowicz E, Regula J, Fijuth J, Kraszewska E, Polkowski M, Wronska E, Butruk E. Rupinski M, et al. Among authors: kraszewska e. Am J Gastroenterol. 2011 Sep;106(9):1612-20. doi: 10.1038/ajg.2011.178. Epub 2011 Jun 14. Am J Gastroenterol. 2011. PMID: 21670770 Clinical Trial.
Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.
Kupryjańczyk J, Szymańska T, Madry R, Timorek A, Stelmachów J, Karpińska G, Rembiszewska A, Ziółkowska I, Kraszewska E, Debniak J, Emerich J, Ułańska M, Płuzańska A, Jedryka M, Goluda M, Chudecka-Głaz A, Rzepka-Górska I, Klimek M, Urbański K, Breborowicz J, Zieliński J, Markowska J. Kupryjańczyk J, et al. Among authors: kraszewska e. Br J Cancer. 2003 Mar 24;88(6):848-54. doi: 10.1038/sj.bjc.6600789. Br J Cancer. 2003. PMID: 12644821 Free PMC article.
TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.
Kupryjańczyk J, Madry R, Plisiecka-Hałasa J, Bar J, Kraszewska E, Ziółkowska I, Timorek A, Stelmachów J, Emerich J, Jedryka M, Płuzańska A, Rzepka-Górska I, Urbański K, Zieliński J, Markowska J. Kupryjańczyk J, et al. Among authors: kraszewska e. Br J Cancer. 2004 Nov 29;91(11):1916-23. doi: 10.1038/sj.bjc.6602238. Br J Cancer. 2004. PMID: 15545967 Free PMC article.
68 results